Helius Medical Tech Q1 2024 GAAP EPS $(3.08) Misses $(2.70) Estimate, Sales $135.000K Beat $130.500K Estimate
Portfolio Pulse from Benzinga Newsdesk
Helius Medical Technologies (HSDT) reported Q1 2024 earnings with a GAAP EPS of $(3.08), missing the $(2.70) estimate, but sales of $135K exceeded the $130.5K forecast. This represents a 30.32% decrease in losses and a 21.62% increase in sales compared to the same period last year.
May 13, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Helius Medical Technologies reported a larger than expected Q1 2024 loss per share but exceeded sales estimates, indicating mixed financial health.
The miss on EPS estimates may concern investors about profitability, while the beat on sales forecasts and year-over-year improvements could signal underlying business strength. The mixed results make the short-term stock price direction uncertain, hence a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100